# Phase II Study of Anti-CD19 CAR-T Cells Treating Leukemia Children

> **NCT04325841** · PHASE2 · COMPLETED · sponsor: **Beijing Boren Hospital** · enrollment: 2 (actual)

## Conditions studied

- Acute Lymphoblastic Leukemia, Pediatric
- Acute Lymphoblastic Leukemia, in Relapse
- Refractory Acute Lymphoblastic Leukemia

## Interventions

- **BIOLOGICAL:** Murine autologous anti-CD19 chimeric antigen receptor T cells

## Key facts

- **NCT ID:** NCT04325841
- **Lead sponsor:** Beijing Boren Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-24
- **Primary completion:** 2024-04-03
- **Final completion:** 2024-04-03
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2025-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04325841

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04325841, "Phase II Study of Anti-CD19 CAR-T Cells Treating Leukemia Children". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04325841. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*